Literature DB >> 18317222

Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.

Tomokazu Umezu1, Kiyosumi Shibata, Hiroaki Kajiyama, Mikio Terauchi, Kazuhiko Ino, Akihiro Nawa, Fumitaka Kikkawa.   

Abstract

The prognostic significance of histology has been well established in epithelial ovarian cancer (EOC). Clear cell and mucinous histologies are especially generally accepted to result in an adverse outcome because of their poor chemotherapy response. Previous reports suggested that class III beta-tubulin induced taxol resistance in association with a reduced effect on microtubule dynamic instability. Thus, this study aimed to evaluate class III beta-tubulin expression and examine whether the protein level of class III beta-tubulin was correlated with the histological difference in chemosensitivity. Class III beta-tubulin expression in EOC tissues (n = 80) was immunohistochemically scored into 4 groups (-, +/-, +, ++). High-level (+, ++) class III beta-tubulin expression was detected in 30 of 35 clear cell carcinomas, in 8 of 10 mucinous carcinomas, 5 of 11 endometrioid carcinomas, and 5 of 24 serous carcinomas. Nineteen patients were evaluable for response. In 5 responders, high-level class III beta-tubulin expression was not detected. On the other hand, it was detected in 10 of 14 nonresponders. In some ovarian cancer cell lines, we evaluated class III beta-tubulin expression by Western blot analysis. Class III beta-tubulin expression in nonserous carcinoma tended to be higher than that in serous carcinoma. Taxol-resistant SKOV cells showed high-level class III beta-tubulin expression compared with wild-type SKOV cells. Taxol sensitivity differing among histological subtypes in EOC is associated with the expression of class III beta-tubulin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317222     DOI: 10.1097/PGP.0b013e318156c838

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  21 in total

1.  Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.

Authors:  Daniel Paik; Emiliano Cocco; Stefania Bellone; Francesca Casagrande; Marta Bellone; Eric E Siegel; Christine E Richter; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2010-07-31       Impact factor: 5.482

2.  Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.

Authors:  Luisa Carrara; Federica Guzzo; Dana M Roque; Stefania Bellone; Cocco Emiliano; Enrico Sartori; Sergio Pecorelli; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2011-12-29       Impact factor: 5.482

3.  Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.

Authors:  Dana M Roque; Natalia Buza; Michelle Glasgow; Stefania Bellone; Ileana Bortolomai; Sara Gasparrini; Emiliano Cocco; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2013-09-05       Impact factor: 5.150

4.  Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance.

Authors:  Yuan Tian; Aik-Choon Tan; Xiaer Sun; Matthew T Olson; Zhi Xie; Natini Jinawath; Daniel W Chan; Ie-Ming Shih; Zhen Zhang; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2009-11       Impact factor: 3.494

5.  A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.

Authors:  Carolyn K McCourt; Wei Deng; Don S Dizon; Heather A Lankes; Michael J Birrer; Michele M Lomme; Matthew A Powell; James E Kendrick; Joel N Saltzman; David Warshal; Meaghan E Tenney; David M Kushner; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2016-10-28       Impact factor: 5.482

6.  Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Authors:  Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

7.  Neurogenesis and neurite outgrowth in the spinal cord of chicken embryos and in primary cultures of spinal neurons following knockdown of Class III beta tubulin with antisense morpholinos.

Authors:  Richard P Tucker; Ha Tran; Qizhi Gong
Journal:  Protoplasma       Date:  2008-09-30       Impact factor: 3.356

8.  Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Authors:  Diana M Cittelly; Irina Dimitrova; Erin N Howe; Dawn R Cochrane; Annie Jean; Nicole S Spoelstra; Miriam D Post; Xian Lu; Russell R Broaddus; Monique A Spillman; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2012-10-16       Impact factor: 6.261

9.  The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin.

Authors:  Wenting He; Dachuan Zhang; Jingting Jiang; Ping Liu; Changping Wu
Journal:  Med Oncol       Date:  2014-04-11       Impact factor: 3.064

10.  MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.

Authors:  Dawn R Cochrane; Nicole S Spoelstra; Erin N Howe; Steven K Nordeen; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2009-05-12       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.